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Introduction 
Histamine plays important roles in various brain functions, such as arousal, attention, 
and cognition1,2). On the other hand, antihistamines often have sedative side effects. The 
adverse effects are mainly due to the ability of antihistamines to penetrate the blood–brain 
barrier, blocking neuronal transmission in the histaminergic nervous system in the brain. We 
have studied brain functional changes because of sedative effect of antihistamines. This time, 
we investigated the regional brain activity during cognitive tasks after administration of 
sedative and non-sedative antihistamines in terms of cerebral glucose metabolic changes and 
examined its relationship with regional hemodynamic response. 
 
Materials and Methods 
Eighteen healthy young volunteer (21.7 ± 0.8 years) participated in the study. This 
study used a double-blind, placebo-controlled, three-way, crossover design. Single doses of 
levocetirizine 5 mg, diphenhydramine 50 mg, and placebo (lactobacillus tablets) were 
administered orally with 100 mL water. Treatment periods were separated by a washout 
period of at least 6 days. The first PET scan (PET1) was performed in the resting state before 
oral administration (baseline) and the second PET scan (PET2) was done at 120 min post-
administration (Fig. 1). The cognitive testing battery consisted of the word fluency test 
(Task1), two-back test (Task2), and Stroop test (Task3), all of which were prepared to activate 
the prefrontal cortex. Each of the three tasks took 60 s and each task was separated by 20-s-
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long pre-task and post-task resting phases. A session including the three tasks was repeated 
six times, taking 30 min in total (Fig. 1). Also, assessment of subjective sleepiness was 
performed with the Stanford Sleepiness Scale (SSS) and the line analog rating scale (LARS); 
(Fig. 1).  
We investigated cerebral glucose metabolic changes using positron emission 
tomography (PET). Brain scans were performed by the Eminence STARGATE PET scanner 
(Shimadzu Corp., Kyoto, Japan). Subjects were first scanned in the "resting" control 
condition (PET1) and later in the "task" condition (PET2) to compare the regional brain 
metabolic changes due to antihistamines (Fig. 1). PET brain images were transformed into 
those reflecting standardized uptake values (SUVs), normalized by body weight and by 
injected radioactivity of FDG. These SUV images were analyzed to identify regional changes 
in glucose consumption using a software package, Statistical Parametric Mapping (SPM8; 
Functional Imaging Laboratory, London, UK)3), which performed voxel-by-voxel analysis. 
During the cognitive tasks, hemodynamic responses were recorded as changes in oxygenated 
hemoglobin concentrations (Δoxy-Hb) in the frontal cortex using the OMM-3000 System 
(Shimadzu Corp., Kyoto, Japan). In the present study protocol, the first cognitive task (word 
fluency task: Task1) was initiated after the pre-task resting period and lasted for 60 s; this was 
followed by other post-task and pre-task resting periods and then the second task (20 s each). 
Then, the second (two-back task: Task2) and the third (Stroop task: Task3) tasks were 
assigned in a similar manner. Thus, the set of three cognitive tests was repeated six times (Fig. 
1). The cerebral hemodynamic response pattern was examined for each task and for each drug 
treatment condition. For NIRS data analysis in the present study, we focused on the increase 
of oxy-Hb concentration which is considered as an estimate of regional brain activation. The 
oxy-Hb data were also corrected baseline offset (zero) to the task-starting time (t= 0) and 
were transformed into Δoxy-Hb data, and were averaged to demonstrate hemodynamic 
responses in bilateral prefrontal areas during tasks for the three drug treatment conditions. 
ΔOxy-Hb waveforms values were averaged throughout the task phase (0 to 60 s) for statistical 
examination. 
For statistical analyses, we used SPSS 22.0 (Japanese version). For the subjective 
sedation, SSS and LARS scores were both examined by applying non-parametric 
examinations such as the Friedman test and Wilcoxon signed rank test (two-tailed; p ≤ .05). 
All results of cognitive tests, including word counts in word fluency tests and accuracy and 
reaction time in two-back and Stroop tests, were also examined between drug treatments 
using non-parametric methods such as the Friedman test and Wilcoxon signed rank test (two-
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tailed; p ≤ .05). For the statistical analyses of PET images, the repeated ANOVA option of the 
SPM8 software package was applied because normal distribution and equal variance were 
confirmed. Significant findings were additionally examined by post hoc multiple pairwise 
treatment comparisons using a Bonferroni test (two-tailed; p ≤ .05). For the statistical analyses 
of NIRS data, non-parametric examinations such as the Friedman test and Wilcoxon signed 
rank test (two-tailed; p ≤ .05) were applied because normal distribution and equal variance 
were not confirmed. Significant findings were additionally examined by post hoc multiple 
pairwise treatment comparisons using the Wilcoxon signed rank test (two-tailed; p ≤ .05). 
Details are described in our published paper4). 
The ethics committee of the University Graduate School of Medicine approved the 
study protocol. 
 
Results and Discussion 
Subjective feelings were no significant differences between placebo and treatment 
conditions. Performance in Stroop test (accuracy) was significantly impaired after treatment 
with the sedative antihistamine compared with both the placebo (p = .008) and levocetirizine 
treatment (p = .001).  
FDG-PET analysis using SPM8 revealed significant regional brain changes in glucose 
consumption during cognitive tasks (PET2) compared with the pre-treatment resting images 
(PET1) for each drug treatment condition (Fig. 2). Notably, the activation in Broca’s area 
(Brodmann area: BA44/45), BA9, and BA10 was observed in all treatment conditions. 
Regional energy consumption was more prominent and more extensive with antihistamine 
treatments than with placebo in the following order: diphenhydramine > levocetirizine > 
placebo. 
Hemodynamic responses were examined in the prefrontal regions that showed 
significant activation in FDG-PET (BA9, -10, and -44/45). Prefrontal activation (ΔOxy-Hb) 
was much more prominent during Task1 than during the other tasks. Thus, activation during 
Task2 and Task3 was much less prominent. In terms of temporal analysis, cortical activation 
patterns during Task1 in BA9, -10, and -44/45 were compared in both hemispheres (Fig. 3). 
Basically, there was no clear difference in shape of Δoxy-Hb waveforms between drug 
treatments (Fig. 3). In the all treatment conditions, there was an initial small peak (at 5 s after 
task onset) and the highest peak (at 60 to 70 s after task onset) in hemodynamic responses. 
There were some significant differences between hemispheres and between treatment 
conditions, with the general trend for higher activation following placebo treatment than 
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following antihistamine treatment (Fig. 3). So, hemodynamic responses during the word 
fluency task seemed to be suppressed by antihistamine treatment compared with placebo (Fig. 
3), as previously demonstrated by Tsujii and colleagues5).  
FDG-PET results and NIRS results seem to be contradictory based on the “coupling” 
theory (linear correlation between the regional energy consumption and perfusion), where 
slight increased consumptions of oxygen and glucose due to regional brain activation are 
followed by a rapid and considerable surge in oxygen and glucose concentrations due to rapid 
capillary dilations in the activated brain regions. Thus, in principle, brain activation should 
be accompanied by a marked increase in oxy-Hb concentration. Antihistamines might 
possibly suppress the permeability of brain capillaries, dulling the prompt hemodynamic 
responses. However, such suppression might complicate continuous hemodynamic responses 
(up to 30 min, as in the present study). 
 
Conclusion 
Under sedative condition of administrating antihistamine, physiological “coupling” 
between metabolism and perfusion in the healthy human brain may not be maintained. This 
uncoupling may be caused by a combination of increased energy demands in the prefrontal 
regions and suppression of vascular permeability in brain capillaries after antihistamine 
treatment. Further research is needed to elucidate this mechanism. 
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Figure 1.  Schematic diagrams of the entire study protocol (top) and of the 
cognitive test protocol. FDG, [18F]fluorodeoxyglucose; LARS, line analog rating 
scale; NIRS, near‐infrared spectroscopy; PET, positron emission tomography; 
SSS, Stanford Sleepiness Scale (Reproduced from Ref.4). 
 
 
Figure 2.  Results of voxel‐by‐ voxel statistical parametric analysis of positron emission 
tomography [18F]fluorodeoxyglucose images. Statistically significant voxels are presented in the 
transparent standard brain space (glass brain, top) and superimposed onto the standard magnetic 
resonance imaging brain template images (bottom). The metabolic results of a voxel‐by‐ voxel 
comparison of regional cerebral glucose metabolic images using statistical parametric mapping 
(SPM8; height threshold, p < .05, corresponding to z value >3.1; extent threshold 10 voxel 
minimum, with correction for multiple comparisons). L, left hemisphere; R, right hemisphere 
(Reproduced from Ref.4) 
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Figure 3.  Changes in oxygenated hemoglobin (Δoxy‐Hb) waveforms showing cortical 
activation patterns during word fluency task (Task1) in BA9, BA10, and BA44/BA45 in 
the left and right hemispheres measured with near‐infrared spectroscopy (left and middle 
columns). Results of statistical examination regarding the quantitative analysis of 
activation (right column). *p < .05, **p < .001 for the post hoc Wilcoxon signed rank test. 
BA, Brodmann area; Lt., left; Rt., right; Pla, placebo; Lev, levocetirizine; Dip, 
diphenhydramine; oxy‐Hb, oxygenated haemoglobin (Reproduced from Ref.4). 
